Download MendeleyUnique binding mode of Evogliptin with human dipeptidyl peptidase IV.
Lee, H.K., Kim, M.K., Kim, H.D., Kim, H.J., Kim, J.W., Lee, J.O., Kim, C.W., Kim, E.E.(2017) Biochem Biophys Res Commun 494: 452-459
- PubMed: 29061303
- DOI: https://doi.org/10.1016/j.bbrc.2017.10.101
- Primary Citation of Related Structures:
5Y7H, 5Y7J, 5Y7K - PubMed Abstract:
Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl) piperazine-2-one)) is a highly potent selective inhibitor of dipeptidyl peptidase IV (DPP4) that was approved for the treatment of type 2 diabetes in South Korea. In this study, we report the crystal structures of Evogliptin, DA-12166, and DA-12228 (S,R diastereomer of Evogliptin) complexed to human DPP4. Analysis of both the structures and inhibitory activities suggests that the binding of the trifluorophenyl moiety in the S 1 pocket and the piperazine-2-one moiety have hydrophobic interactions with Phe357 in the S 2 extensive subsite, and that the multiple hydrogen bonds made by the (R)-β-amine group in the S 2 pocket and the contacts made by the (R)-tert-butyl group with Arg125 contribute to the high potency observed for Evogliptin.
Organizational Affiliation:
Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea; Dong-A Socio R&D Center, Yongin, Republic of Korea; School of Life Sciences and Biotechnology Korea University, Seoul, Republic of Korea.
